[Combined radiotherapy and hormone therapy in non metastatic adenocarcinoma of prostate].
Non metastatic adenocarcinoma of prostate can be cured in the vast majority of cases with surgery and/or external or interstitial radiotherapy. Failures are much more frequent when tumours are locally advanced. For this reason, new strategies have been designed, among them combined radiotherapy and hormonotherapy, in most cases with a LHRH analog, neoadjuvant and/or concomitant and/or adjuvant. Analysis of results of recent randomised trials comparing this association and exclusive radiotherapy allows for validating concept of combined radiotherapy and hormono therapy in locally advanced adenocarcinoma of prostate, while many questions should be more clearly answered.
Mazeron
Jean-Jacques
JJ
Service de radiothérapie oncologique, Groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, Boulevard de l'Hôpital, 75651 Paris cedex 13. jean-Jacques.mazeron@psl.aphp.fr
Simon
Jean-Marc
JM
Toubiana
Thierry
T
Lang
Philippe
P
D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal